The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
In contrast to all that, many investors prefer to focus on companies like Aier Eye Hospital Group (SZSE:300015), which has not only revenues, but also profits. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
Check out our latest analysis for Aier Eye Hospital Group
How Quickly Is Aier Eye Hospital Group Increasing Earnings Per Share?
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Impressively, Aier Eye Hospital Group has grown EPS by 26% per year, compound, in the last three years. This has no doubt fuelled the optimism that sees the stock trading on a high multiple of earnings.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. While Aier Eye Hospital Group did well to grow revenue over the last year, EBIT margins were dampened at the same time. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead.
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.
SZSE:300015 Earnings and Revenue History September 7th 2022
Fortunately, we've got access to analyst forecasts of Aier Eye Hospital Group's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.
Are Aier Eye Hospital Group Insiders Aligned With All Shareholders?
Since Aier Eye Hospital Group has a market capitalisation of CN¥194b, we wouldn't expect insiders to hold a large percentage of shares. But we are reassured by the fact they have invested in the company. We note that their impressive stake in the company is worth CN¥41b. This totals to 21% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. So there is opportunity here to invest in a company whose management have tangible incentives to deliver.
It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Well, based on the CEO pay, you'd argue that they are indeed. For companies with market capitalisations over CN¥55b, like Aier Eye Hospital Group, the median CEO pay is around CN¥2.3m.
The Aier Eye Hospital Group CEO received CN¥1.1m in compensation for the year ending December 2021. That seems pretty reasonable, especially given it's below the median for similar sized companies. While the level of CEO compensation shouldn't be the biggest factor in how the company is viewed, modest remuneration is a positive, because it suggests that the board keeps shareholder interests in mind. It can also be a sign of good governance, more generally.
Is Aier Eye Hospital Group Worth Keeping An Eye On?
If you believe that share price follows earnings per share you should definitely be delving further into Aier Eye Hospital Group's strong EPS growth. If you still have your doubts, remember too that company insiders have a considerable investment aligning themselves with the shareholders and CEO pay is quite modest compared to similarly sized companiess. The overarching message here is that Aier Eye Hospital Group has underlying strengths that make it worth a look at. What about risks? Every company has them, and we've spotted 1 warning sign for Aier Eye Hospital Group you should know about.
The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
投资一家能够扭转命运的公司所带来的兴奋,对一些投机者来说是一个巨大的吸引力,因此,即使是没有收入、没有利润、业绩不佳的公司,也能设法找到投资者。但现实是,当一家公司每年亏损时,在足够长的时间内,投资者通常会承担他们的损失份额。一家亏损的公司还没有用盈利来证明自己,最终外部资本的流入可能会枯竭。
与此形成鲜明对比的是,许多投资者更倾向于关注像爱尔眼科医院集团(上证所:300015),不仅有收入,而且有利润。虽然这并不一定意味着它是否被低估了,但该业务的盈利能力足以证明它有一定的升值价值--特别是如果它在增长的话。
查看我们对爱尔眼科医院集团的最新分析
爱尔眼科医院集团每股收益增长速度有多快?
一般来说,经历每股收益(EPS)增长的公司应该会看到类似的股价趋势。因此,有很多投资者喜欢购买每股收益不断增长的公司的股票。令人印象深刻的是,艾尔眼科医院集团在过去三年中以每年26%的复合增长率增长每股收益。这无疑助长了人们的乐观情绪,认为该股的市盈率很高。
仔细考虑收入增长和息税前利润(EBIT)利润率有助于了解最近利润增长的可持续性。虽然艾尔眼科医院集团去年的收入增长良好,但息税前利润也受到了抑制。如果息税前利润能够保持平衡,收入增长继续下去,那么我们应该会看到未来更光明的日子。
下面的图表显示了该公司的利润和收入是如何随着时间的推移而变化的。要查看更详细的信息,请点击图片。
深交所:300015年度盈利及收入历史2022年9月7日
幸运的是,我们已经获得了艾尔眼科医院集团的分析师预测未来利润。你可以不看就做你自己的预测,或者你可以偷看一下专业人士的预测。
艾尔眼科医院集团内部人士是否与所有股东一致?
由于爱尔眼科医院集团的市值为人民币1940亿元,我们预计内部人士不会持有很大比例的股份。但让我们放心的是,他们对该公司进行了投资。我们注意到他们在该公司令人印象深刻的股份价值410亿元人民币。这相当于该公司21%的股份。足以引导管理层的决策过程走上为股东带来最大利益的道路。因此,这里有机会投资于一家管理层具有切实激励措施的公司。
看到内部人士投资于这项业务意义重大,但股东们可能会想,薪酬政策是否符合他们的最佳利益。嗯,根据CEO的薪酬,你会说他们确实是这样的。对于市值超过550亿加元的公司,如爱尔眼科医院集团,CEO薪酬中值约为230万加元。
这位爱尔眼科医院集团首席执行官在截至2021年12月的一年中获得了110万加元的薪酬。这似乎相当合理,特别是考虑到它低于类似规模公司的中值。虽然CEO的薪酬水平不应该是人们如何看待公司的最大因素,但适度的薪酬是一个积极的因素,因为它表明董事会考虑到了股东的利益。更广泛地说,这也可能是良好治理的标志。
爱尔眼科医院集团值得关注吗?
如果你相信股价跟随每股收益,你肯定应该进一步研究艾尔眼科医院集团强劲的每股收益增长。如果你仍有疑问,还请记住,公司内部人士有相当大的投资来与股东保持一致,与类似规模的公司相比,CEO的薪酬相当低。这里最重要的信息是,艾尔眼科医院集团拥有潜在的优势,值得一看。那么风险呢?每家公司都有它们,我们已经发现爱尔眼科医院集团的1个警告标志你应该知道。
投资的美妙之处在于,你几乎可以投资任何你想投资的公司。但如果你更愿意关注那些表现出内幕收购的股票,这里有一份过去三个月内有内幕收购的公司名单。
请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。